<DOC>
	<DOCNO>NCT01115036</DOCNO>
	<brief_summary>In current study , investigator evaluate intratumoral pharmacodynamic pharmacokinetic data associate administration HDACI , Panobinostat , among recurrent GBM patient . In addition , study evaluate safety tolerability agent , well evidence anti-tumor activity patient population .</brief_summary>
	<brief_title>A Panobinostat Presurgery</brief_title>
	<detailed_description>This study enroll maximum 24 subject recurrent GBM schedule plan debulking craniotomy . After screen enrollment study , subject receive 20mg panobinostat 3 time week one week prior surgery . Within 2-6 week resection , subject resume panobinostat 20mg panobinostat 3 time per week . The primary endpoint 6-month progression-free survival . Each cycle therapy 28 day . All subject assess every cycle therapy . Subjects remain study therapy least one year unless develop progressive disease , unacceptable toxicity , non-compliance study procedure withdraw consent . Patients may continue treatment oral panobinostat experience unacceptable toxicity precludes treatment , disease progression , and/or discretion investigator .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Patient age ≥ 18 year Histologicallyconfirmed grade 4 malignant glioma patient ; Candidate surgical resection tumor ; No 3 prior episode progressive disease ; An interval least 4 week prior surgical resection two week stereotactic biopsy ; An interval least 12 week end prior radiotherapy unless new area enhancement consistent recurrent tumor outside radiation field , progressive change MRI least two consecutive MRI scan least four week apart , biopsyproven tumor progression ; An interval least 4 week prior chemotherapy ( 6 week nitrosoureas ) investigational agent , unless patient recover anticipated toxicity associate therapy ; Karnofsky * 70 % ; Hemoglobin ≥ 9 g/dL , ANC &gt; 1,500 cells/*l , platelet &gt; 150,000 cells/*l ; Serum creatinine &lt; 1.5 mg/dl 24hour creatinine clearance ≥ 50 ml/min , serum SGOT bilirubin &lt; 1.5 time upper limit normal ; total serum calcium ( correct serum albumin ) ionize calcium ≥ LLN ; serum potassium ≥ LLN ; serum sodium ≥ LLN ; serum albumin ≥ LLN 3g/dl ; Clinically euthyroid ( Note : Patients permit receive thyroid hormone supplement treat underlying hypothyroidism ) ; Baseline MUGA ECHO must demonstrate LVEF ≥ low limit institutional normal ; Ability provide write informed consent obtain prior participation study relate procedure perform ; Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer Patients need valproic acid medical condition study within 5 day prior first panobinostat treatment ; Use CYP3A induce antiepileptic ( phenytoin , fosphenytoin , carbamazepine , oxcarbazepine , phenobarbitol , primidone ) ; Pregnancy breast feeding ; Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid ; Active infection require intravenous antibiotic ; Prior bevacizumab within 6 week study enrollment ; Therapeutic anticoagulation warfarin , aspirin , nonsteroidal antiinflammatory drug clopidogrel ; Impaired cardiac function include one following : Complete leave bundle branch block use permanent cardiac pacemaker , congenital long QT syndrome , history presence ventricular tachyarrhythmias , clinically significant rest bradycardia ( &lt; 50 beat per minute ) , QTcF &gt; 450 msec screen ECG , right bundle branch block + leave anterior hemiblock ( bifascicular block ) ; Presence atrial fibrillation ( ventricular heart rate &gt; 100 bpm ) ; Previous history angina pectoris acute MI within 6 month ; Congestive heart failure ( New York Heart Association functional classification IIIIV ) baseline MUGA/Echo show LVEF &lt; 45 % ; Uncontrolled hypertension ; Concomitant use drug risk cause Torsades de pointes ( See Table 141 ) ; Patients unresolved diarrhea ≥ grade 2 ; Patients ≥ grade 2 peripheral neuropathy ; Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral panobinostat ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , obstruction , stomach and/or small bowel resection ) Other concurrent severe and/or uncontrolled medical condition ; Concomitant use anticancer therapy radiation therapy ; Patients history another primary malignancy within 5 year curatively treat carcinoma situ cervix , basal squamous cell carcinoma skin ; Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require ; Patients significant history noncompliance medical regimen inability grant reliable informed consent . Women childbearing potential ( WOCBP ) willing use double barrier method contraception study 3 month end treatment . One method contraception must barrier method . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day first administration oral panobinostat ; Male patient whose sexual partner WOCBP use double method contraception study 3 month end treatment . One method must condom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>recurrent</keyword>
	<keyword>surgical resection</keyword>
</DOC>